NOW Hyglos - Profos AG is purchased by private investors
Profos AG founded from Regensburg University in 2000 was one of the first companies in BioPark Regensburg and has been a contracting party since 2006 to the biotech company bioMérieux listed on the Paris Stock Exchange (NYSE Euronext BIM – ISIN: FR0010096479). Profos AG has now been bought by Hyglos Invest GmbH, an investment holding company founded in 2009. Hyglos GmbH is functioning as a successor company with everything remaining the same for the customers and business partners at Profos AG, aside from the change in company data. With bioMérieux as co-investor, Hyglos is now in direct contact with one of the global market leaders in medical and industrial in-vitro diagnostics, with 38 regional offices worldwide and a wide distribution network. The focus of Hyglos GmbH lies in the production and marketing of products and services developed in the last few years on the basis of phage protein technology. Several projects have reached production standard and in addition to the established portfolio with the two product groups “Endoline“ and “Food Diagnostics“, introduction of further products are planned. The investors have set the company on a healthy financial base to guarantee sustainable financial success of the new company.
For more information see: